ClinicalTrials.gg
RecruitingNCT07027046Updated Nov 19, 2026

Application of da Vinci SP for Endometrial Cancer Surgical Staging

An observational study in Endometrial Cancer, sponsored by National Cancer Institute, Naples. Recruiting at 3 sites in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by National Cancer Institute, Naples · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 19, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
564
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Endometrial Neoplasms with a site in Italy — 70 open to participants now, 87 under way, 16 of them phase 3. Endometrial Neoplasms · Italy.

Planned enrollment
12th of 42
564 · median 200
Started
2025
with 19 others
Observational
42 of 139
31 open now
Primary completion
2027-06
later than 45 of 86 live
Registered
121st of 139
by date
Lead sponsor
7 of 139
National Cancer Institute, Naples

Among the 139 studies in Endometrial Neoplasms with a site in Italy, this one is the 12th largest by planned enrollment of the 42 observational ones that give a count, is one of 20 that started in 2025, is one of 42 observational ones, reaches primary completion later than 45 of the 86 other live ones, and was the 121st registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

70 of the 139 studies in Endometrial Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

64 more — sign in →

All 70 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Endometrial Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

Prospective Multicenter Observational Study The study involves the consecutive inclusion of every patient with endometrial cancer undergoing staging surgical treatment using a robotic approach with the da Vinci SP platform.

Read the detailed description

The standard treatment for early-stage endometrial cancer is surgical staging, which includes total hysterectomy with bilateral salpingo-oophorectomy and surgical lymph node assessment.

The well-known advancements in minimally invasive surgery (MIS) have enabled laparoscopic and robotic surgical staging in gynecologic oncology. In the case of endometrial cancer, MIS is indeed the preferred surgical approach. Following the approval of the da Vinci Surgical System (Intuitive Surgical, Sunnyvale, CA, USA) for gynecological procedures by the United States Food and Drug Administration in 2005, the use of robotic surgery for endometrial cancer has significantly increased, with favorable outcomes even compared to conventional laparoscopy.

The growing need for increasingly less invasive surgical options has led to the development of the possibility to perform endometrial cancer surgical staging through a single abdominal incision. Despite several attempts to apply single-incision techniques to laparoscopy in the context of endometrial cancer, the standard minimally invasive approach for hysterectomy remains the four-trocar laparoscopic technique. One of the main reasons is that introducing both the endoscope and instruments through a single incision creates internal and external conflicts between instruments and the surgeon's hands. The parallel placement of surgical instruments leads to clashes and restricts the range of motion.

To overcome these limitations, robotic technology may be applied to the single-incision technique. The recent introduction of single-port robotic surgery with the fourth-generation da Vinci® SP Surgical System represents a technological advancement. In fact, the system's flexible articulation of instruments allows for more effective manipulation while reducing instrument collisions. Moreover, the flexible camera provides a new operational angle in all directions.

The new da Vinci SP Surgical System (SP) received regulatory approval for use in gynecologic surgery in Italy in 2024. However, to date, studies in the literature on the use of the da Vinci SP robot in patients with endometrial cancer are limited due to the relatively small number of patients, single-center settings, and the retrospective nature of most studies.

Because of these limitations in the literature, definitive evidence is still lacking regarding the efficacy and safety profile of the da Vinci SP in surgical staging of early-stage endometrial cancer.

Based on these premises, the aim of this study is to clarify the outcomes associated with this minimally invasive robotic approach by reporting one of the first experiences of robotic surgical staging for endometrial cancer using the new da Vinci SP robotic platform.

The primary objective of the study is to evaluate the surgical efficacy profile of the minimally invasive robotic approach using the da Vinci SP platform for the surgical staging of endometrial cancer.

03

Conditions studied

  • Endometrial Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women with histologically confirmed endometrial carcinoma at first diagnosis who have planned staging surgery for endometrial cancer to be performed using the robotic approach with the da Vinci SP platform

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • confirmed endometrial carcinoma (including uterine carcinosarcoma)
  • Performance status () 0 - 1
  • Patients undergoing staging surgery for endometrial cancer, including but not limited to robotic hysterectomy with bilateral salpingo-oophorectomy (ovarian preservation in selected patients is not an exclusion criterion) and possible sentinel lymph node /pelvic ± para-aortic lymphadenectomy
  • Signed to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Patients scheduled for an additional extra-genital surgical procedure during the staging surgery for endometrial carcinoma
  • Patients with anesthesiological to a minimally invasive approach
  • Synchronous tumor
  • Recurrence of endometrial carcinoma
  • Dementia or significantly altered mental status that may impair understanding and the ability to provide
  • Any reason that may interfere with regular follow-up, even if limited to the first 30 days post-surgery
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
564 participants (estimated)
Patient registry
No

Groups and cohorts

  • Da Vinci SP Surgical Staging Group

    Patients with early-stage endometrial cancer undergoing robotic surgical staging using the Da Vinci SP system.

    Procedure: Robotic surgical staging

Interventions

  • ProcedureRobotic surgical staging

    The intervention includes hysterectomy, bilateral salpingo-oophorectomy, and sentinel lymph node mapping, with possible lymphadenectomy or omentectomy, depending on histology.

06

What researchers measure

Primary outcomes

  1. Rate of satisfactory completion of staging surgery according to the criteria of national and international guidelines for the treatment of endometrial carcinoma.

    Time frame: 12 months

  2. Rate of intraoperative complications, after categorization based on the type of complication and the timing of its occurrence.

    Time frame: 12 months

  3. Rate of postoperative complications, after categorization based on the type of complication (within 30 days after surgery, after 30 days post-surgery) and according to the Clavien-Dindo classification.

    Time frame: 48 months

Secondary outcomes

  1. Disease-Free Survival (DFS) calculated from the date of randomization to the date of death from any cause or censored at the date of the last follow-up, after categorization based on molecular class and tumor prognostic factors.

    Time frame: up to 48 months (4 years)

  2. Overall Survival (OS) calculated from the date of randomization to the date of death from any cause or censored at the date of the last follow-up, after categorization based on molecular class and tumor prognostic factors.

    Time frame: up to 48 months (4 years)

  3. Quality of Life (QoL) assessed using the questionnaires from the EORTC QLQ-C30 (Version 3).

    Time frame: From baseline (pre-treatment) up to 48 months (4 years) post-randomization, with assessments every 6 months

  4. Quality of Life (QoL) assessed using the questionnaires from EORTC QLQ-OV28.

    Time frame: From baseline (pre-treatment) up to 48 months (4 years) post-randomization, with assessments every 6 months

  5. Quality of Life (QoL) assessed using the questionnaires from the EQ-5D-3L.

    Time frame: From baseline (pre-treatment) up to 48 months (4 years) post-randomization, with assessments every 6 months

07

Study locations

3 of 3 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jun 2027, 26 months after the start.

Of 130 non-industry observational studies under Endometrial Neoplasms, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 206. This study's planned 26 months is below that.

Counting every sponsor, half of 150 studies reached it within 105 months; a quarter within 32 and three quarters within 206.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jun 2027, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jun 18, 2025
StartActual
Apr 3, 2025
Primary completionEst.
Jun 2027was Jun 2026
CompletionEst.
Jun 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Jun 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Primary completion Jun 2026→Jun 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07027046
Responsible party
Sponsor
First posted
Jun 18, 2025
Start date
Apr 3, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Giuseppe Cucinella, MD
Contact
giuseppe.cucinella@istitutotumori.na.it
00000000000
Vito Chiantera, MD
principal investigator · IRCCS I.N.T. "G. Pascale"

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion